2nd Quarter - Report — HARM REDUCTION COALITION for HARM REDUCTION COALITION (2015)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm

HARM REDUCTION COALITION

Client

HARM REDUCTION COALITION

Income

$20,000

Expenses

—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
2nd Quarter - Report (this page)	Jul 27, 2015	$20,000	Replaced
2nd Quarter - Termination	Sep 8, 2017	$20,000	Replaced
2nd Quarter - Termination Amendment	Nov 6, 2017	—	Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Viral hepatitis and HIV/AIDS prevention and treatment

Lobbyist	Covered position, as disclosed
WHITNEY ENGLANDER	—

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Substance Abuse & Mental Health Services Administration (SAMHSA); Natl Institutes of Health (NIH); Office of Natl Drug Control Policy (NDCP); SENATE

Alcohol and Drug Abuse ALC

Issues related to the opioid epidemic and their attendant health consequences, including substance use disorder, overdose, infectious disease and neonatal abstinence syndrome.

Lobbyist	Covered position, as disclosed
WHITNEY ENGLANDER	—

Contacted: Food & Drug Administration (FDA); Office of Natl Drug Control Policy (NDCP); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; SENATE; Substance Abuse & Mental Health Services Administration (SAMHSA); Natl Institutes of Health (NIH)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.